Tango Therapeutics, Inc. financial data

Symbol
TNGX on Nasdaq
Location
201 Brookline Avenue, Suite 901, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 647 % -18.5%
Debt-to-equity 61.7 % +11.5%
Return On Equity -79.7 % -78.2%
Return On Assets -49.3 % -71.2%
Operating Margin -647 % -108%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 111M shares +3.84%
Common Stock, Shares, Outstanding 111M shares +3.58%
Entity Public Float 855M USD +382%
Common Stock, Value, Issued 111K USD +3.74%
Weighted Average Number of Shares Outstanding, Basic 111M shares +2.06%
Weighted Average Number of Shares Outstanding, Diluted 111M shares +2.06%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 24.3M USD -42.8%
Research and Development Expense 136M USD +0.92%
General and Administrative Expense 45.1M USD +13.5%
Operating Income (Loss) -157M USD -18.8%
Nonoperating Income (Expense) 11.9M USD -26.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -145M USD -25%
Income Tax Expense (Benefit) 172K USD -1.71%
Net Income (Loss) Attributable to Parent -146M USD -25%
Earnings Per Share, Basic -1 USD/shares -17%
Earnings Per Share, Diluted -1 USD/shares -17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.3M USD -23.8%
Marketable Securities, Current 142M USD -47.7%
Cash, Cash Equivalents, and Short-term Investments 181M USD
Assets, Current 190M USD -42.1%
Property, Plant and Equipment, Net 7.79M USD -14.4%
Operating Lease, Right-of-Use Asset 37.6M USD -9.22%
Other Assets, Noncurrent 310K USD +3000%
Assets 238M USD -37.6%
Accounts Payable, Current 2.61M USD +145%
Employee-related Liabilities, Current 5.6M USD +3.17%
Contract with Customer, Liability, Current 23.4M USD -1.24%
Liabilities, Current 40M USD -8.76%
Contract with Customer, Liability, Noncurrent 30.4M USD -44.1%
Operating Lease, Liability, Noncurrent 32.5M USD -8.45%
Liabilities 103M USD -23.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 94K USD
Retained Earnings (Accumulated Deficit) -580M USD -33.5%
Stockholders' Equity Attributable to Parent 135M USD -45.5%
Liabilities and Equity 238M USD -37.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41.7M USD -10.1%
Net Cash Provided by (Used in) Financing Activities 43M USD
Net Cash Provided by (Used in) Investing Activities 30.6M USD
Common Stock, Shares Authorized 400M shares +100%
Common Stock, Shares, Issued 111M shares +3.58%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.1M USD -82.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.8M USD -22.7%
Deferred Tax Assets, Valuation Allowance 156M USD +37.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 169M USD +32.6%
Depreciation 622K USD -0.48%
Payments to Acquire Property, Plant, and Equipment 51K USD -73.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -145M USD -25.9%
Property, Plant and Equipment, Gross 17.4M USD +7.28%
Operating Lease, Liability, Current 2.53M USD +7.19%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 30.6M USD +84.8%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 715M USD +4.75%
Deferred Tax Assets, Net of Valuation Allowance 12.5M USD -10.9%
Share-based Payment Arrangement, Expense 28.5M USD +18.6%